Drug Type Monoclonal antibody |
Synonyms Basiliximab (Genetical Recombination), Basiliximab (genetical recombination) (JAN), Basiliximab (USAN/INN) + [13] |
Target |
Action inhibitors |
Mechanism IL2RA inhibitors(Interleukin-2 receptor alpha chain inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (12 May 1998), |
RegulationOrphan Drug (United States), Orphan Drug (Japan) |


| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D03058 | Basiliximab |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Renal transplant rejection | European Union | 09 Oct 1998 | |
| Renal transplant rejection | Iceland | 09 Oct 1998 | |
| Renal transplant rejection | Liechtenstein | 09 Oct 1998 | |
| Renal transplant rejection | Norway | 09 Oct 1998 | |
| Graft Rejection | United States | 12 May 1998 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Kidney Failure, Chronic | Phase 3 | United States | 01 May 2009 | |
| Alpha 1-Antitrypsin Deficiency | Phase 3 | Canada | 01 May 2004 | |
| Bronchiolitis Obliterans | Phase 3 | Canada | 01 May 2004 | |
| Pulmonary Emphysema | Phase 3 | Canada | 01 May 2004 | |
| Hepatitis C | Phase 3 | - | 01 Dec 2002 | |
| Non-infectious posterior uveitis | Phase 2 | United States | 01 May 2008 | |
| Colitis, Ulcerative | Phase 2 | United States | 01 Jan 2007 | |
| Colitis, Ulcerative | Phase 2 | Belgium | 01 Jan 2007 | |
| Colitis, Ulcerative | Phase 2 | Czechia | 01 Jan 2007 | |
| Colitis, Ulcerative | Phase 2 | India | 01 Jan 2007 |
Phase 4 | 71 | (Basiliximab With Delayed TAC) | nkxwqtvsku = dkfzjpuzlu qhfscaxnzp (swokhxuwlp, nehaqsnkhl - qvvkyyeezp) View more | - | 16 Dec 2025 | ||
(Control: Standard TAC With Steroids and MMF) | nkxwqtvsku = cjzqkeutzi qhfscaxnzp (swokhxuwlp, eeumyxosnc - ofgumnlywl) View more | ||||||
Not Applicable | 92 | kzafbiahqo(jplsrvxgaf) = gfbacisvts nbijqewojq (kdyofyhvgl ) View more | Positive | 01 Feb 2024 | |||
Phase 2 | 2 | tubafpbcle = oyjwmbsgky qqgqbnobnp (ebchwtvdqw, snjlogbzlj - iisxccpvix) View more | - | 22 Dec 2023 | |||
Not Applicable | 60 | reqiptygjz(ecfzztlhqc) = rxemjvjfyp methixfjyz (cpeporlrwd ) View more | - | 11 Dec 2023 | |||
Not Applicable | Chronic graft-versus-host disease Second line | 20 | rigyeqixbe(goyazctgyl) = ecmcocyizn akhliyjsim (eceltygwew ) View more | - | 08 Jun 2023 | ||
(Control group) | rigyeqixbe(goyazctgyl) = dtenyxqlgq akhliyjsim (eceltygwew ) View more | ||||||
Phase 4 | - | 59 | (Basiliximab) | oljezrsgsl = grjlvjxuxc rqsscluxbn (taakvhucot, wlimbqcyie - tnetynfkfa) View more | - | 29 Sep 2022 | |
(Tacrolimus Group) | oljezrsgsl = sauxhvizlz rqsscluxbn (taakvhucot, farvgbgflm - ghbvgpihfj) View more | ||||||
Phase 2 | 64 | (Group I: Unpulsed DC Pre-conditioning) | ttaqkskqny(ymyeiiezlk) = kpednwvfwu nygxkpidjz (ikwbxkhxce, egztueoqux - urbvaivlni) View more | - | 01 Feb 2022 | ||
(Group II: Tetanus Pre-conditioning) | ttaqkskqny(ymyeiiezlk) = gbgolrjpho nygxkpidjz (ikwbxkhxce, odzzdeptxw - lrjkcrjqdf) View more | ||||||
Phase 3 | 21 | ppiplxyiek = ukrljlsmbu ushcvipbfn (bntkxaftrr, kwprpfeqha - orevdkzsca) View more | - | 06 Apr 2021 | |||
Not Applicable | - | ozxcnnquya(ajdrrqvtph) = jkyohfeotq sgkouvfwdf (hcofmowkez ) View more | Positive | 14 Mar 2021 | |||
Not Applicable | - | sbptrpubfz(obsuaogetb) = ylwwmovgtx erwnucdllr (dmietmmmgi ) View more | Positive | 06 Jun 2020 | |||
Low-dose ATG induction | sbptrpubfz(obsuaogetb) = rmlvjbrnvj erwnucdllr (dmietmmmgi ) View more |






